Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06234748 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer

Study acronym: ARTHOUSE
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Jul 2026 to Jul 2028v4
  2. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 20 to confirmed 19
    • Site details revised
    v3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study seeks to study the population of HPV-related oropharynx cancer patients that appear to be at highest risk for treatment failure with loco-regional failure and distant metastases including cT4 or cN3. The study team aims to determine if it is feasible to use multi-modality imaging (both DCE MRI and FDG-PET) to optimize the radiation boost in high risk p16+ OPSCC with similar or decreased toxicity compared to historic standard therapy.
Trial Details
NCT Number NCT06234748
Lead Sponsor University of Michigan Rogel Cancer Center
Conditions
(from sponsor)		 Oropharynx Cancer, HPV-Related Carcinoma
Related terms Oropharyngeal Neoplasms
Enrollment 19 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov